81 related articles for article (PubMed ID: 7616451)
41. Cell-associated human retinal pigment epithelium interleukin-8 and monocyte chemotactic protein-1: immunochemical and in-situ hybridization analyses.
Elner VM; Burnstine MA; Strieter RM; Kunkel SL; Elner SG
Exp Eye Res; 1997 Dec; 65(6):781-9. PubMed ID: 9441701
[TBL] [Abstract][Full Text] [Related]
42. Differential capacities of CD4+, CD8+, and CD4-CD8- T cell subsets to express IL-18 receptor and produce IFN-gamma in response to IL-18.
Tomura M; Maruo S; Mu J; Zhou XY; Ahn HJ; Hamaoka T; Okamura H; Nakanishi K; Clark S; Kurimoto M; Fujiwara H
J Immunol; 1998 Apr; 160(8):3759-65. PubMed ID: 9558078
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetic basis for optimal hemopoietic effectiveness of homologous IL-3 administered to rhesus monkeys.
van Gils FC; Westerman Y; van den Bos C; Burger H; van Leen RW; Wagemaker G
Leukemia; 1993 Oct; 7(10):1602-7. PubMed ID: 8412321
[TBL] [Abstract][Full Text] [Related]
44. Identification of natural antibodies to interleukin-18 in the sera of normal humans and three nonhuman primate species.
Soos JM; Polsky RM; Keegan SP; Bugelski P; Herzyk DJ
Clin Immunol; 2003 Nov; 109(2):188-96. PubMed ID: 14597217
[TBL] [Abstract][Full Text] [Related]
45. HemaMax™, a recombinant human interleukin-12, is a potent mitigator of acute radiation injury in mice and non-human primates.
Basile LA; Ellefson D; Gluzman-Poltorak Z; Junes-Gill K; Mar V; Mendonca S; Miller JD; Tom J; Trinh A; Gallaher TK
PLoS One; 2012; 7(2):e30434. PubMed ID: 22383962
[TBL] [Abstract][Full Text] [Related]
46. Sterile protection of monkeys against malaria after administration of interleukin-12.
Hoffman SL; Crutcher JM; Puri SK; Ansari AA; Villinger F; Franke ED; Singh PP; Finkelman F; Gately MK; Dutta GP; Sedegah M
Nat Med; 1997 Jan; 3(1):80-3. PubMed ID: 8986746
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers.
García-García I; Hernández-González I; Díaz-Machado A; González-Delgado CA; Pérez-Rodríguez S; García-Vega Y; Campos-Mojena R; Tuero-Iglesias ÁD; Valenzuela-Silva CM; Cruz-Ramírez A; Martín-Trujillo A; Santana-Milián H; López-Saura PA; Bello-Rivero I;
BMC Pharmacol Toxicol; 2016 Dec; 17(1):58. PubMed ID: 27923408
[TBL] [Abstract][Full Text] [Related]
48. The pharmacokinetics and absorption of recombinant human relaxin in nonpregnant rabbits and rhesus monkeys after intravenous and intravaginal administration.
Chen SA; Reed B; Nguyen T; Gaylord N; Fuller GB; Mordenti J
Pharm Res; 1993 Feb; 10(2):223-7. PubMed ID: 8456068
[TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetics and leukocyte responses of recombinant human interleukin-10.
Radwanski E; Chakraborty A; Van Wart S; Huhn RD; Cutler DL; Affrime MB; Jusko WJ
Pharm Res; 1998 Dec; 15(12):1895-901. PubMed ID: 9892475
[TBL] [Abstract][Full Text] [Related]
50. Randomized comparison of single dose of recombinant human IL-12 versus placebo for restoration of hematopoiesis and improved survival in rhesus monkeys exposed to lethal radiation.
Gluzman-Poltorak Z; Mendonca SR; Vainstein V; Kha H; Basile LA
J Hematol Oncol; 2014 Apr; 7():31. PubMed ID: 24708888
[TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetics of PEGylated recombinant human endostatin in rhesus monkeys.
Guo L; Li Z; Xu B; Yu M; Fu Y; Liu L; Wang J; Luo Y
Life Sci; 2019 Dec; 238():116967. PubMed ID: 31626794
[TBL] [Abstract][Full Text] [Related]
52. Immunopharmacology of recombinant human interleukin-18 in non-human primates.
Herzyk DJ; Soos JM; Maier CC; Gore ER; Narayanan PK; Nadwodny KL; Liu S; Jonak ZL; Bugelski PJ
Cytokine; 2002 Oct; 20(1):38-48. PubMed ID: 12441145
[TBL] [Abstract][Full Text] [Related]
53. Pre-clinical toxicokinetics and safety study of M2ES, a PEGylated recombinant human endostatin, in rhesus monkeys.
Guo L; Geng X; Chen Y; Qi F; Liu L; Miao Y; Lin Z; Yu M; Li Z; Fu Y; Li B; Luo Y
Regul Toxicol Pharmacol; 2014 Aug; 69(3):512-23. PubMed ID: 24878240
[TBL] [Abstract][Full Text] [Related]
54. Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration.
Munafo A; Trinchard-Lugan I; Nguyen TX; Buraglio M
Eur J Neurol; 1998 Mar; 5(2):187-193. PubMed ID: 10210831
[TBL] [Abstract][Full Text] [Related]
55. The repeated administration of rhIL-12 for 14 weeks in rhesus monkeys: A toxicity assessment.
Ding H; Qin H; Wang J; Dong Y; Wang Q; Han Y
J Appl Toxicol; 2024 Feb; 44(2):301-312. PubMed ID: 37770382
[TBL] [Abstract][Full Text] [Related]
56. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.
Leonard JP; Sherman ML; Fisher GL; Buchanan LJ; Larsen G; Atkins MB; Sosman JA; Dutcher JP; Vogelzang NJ; Ryan JL
Blood; 1997 Oct; 90(7):2541-8. PubMed ID: 9326219
[TBL] [Abstract][Full Text] [Related]
57. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
[TBL] [Abstract][Full Text] [Related]
58. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Schwartz LH; Olencki T; Malone TM; Sandstrom K; Nadeau R; Parmar H; Bukowski R
Clin Cancer Res; 1998 May; 4(5):1183-91. PubMed ID: 9607576
[TBL] [Abstract][Full Text] [Related]
59. Biologic effects of recombinant human interleukin-12 in squirrel monkeys (Sciureus saimiri).
Sarmiento UM; Riley JH; Knaack PA; Lipman JM; Becker JM; Gately MK; Chizzonite R; Anderson TD
Lab Invest; 1994 Dec; 71(6):862-73. PubMed ID: 7807968
[TBL] [Abstract][Full Text] [Related]
60. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma.
Bajetta E; Del Vecchio M; Mortarini R; Nadeau R; Rakhit A; Rimassa L; Fowst C; Borri A; Anichini A; Parmiani G
Clin Cancer Res; 1998 Jan; 4(1):75-85. PubMed ID: 9516955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
